Evidence map›Paper›PMID 42488678›Full record

ArticleFrontiers in immunology2026

Efficacy and safety of combining radiotherapy with first-line chemotherapy and immunotherapy for local advanced/metastatic urothelial cancer: a propensity score matching analysis.

Jian Qin, Hanjing Zhou, Xia Li, Hubin Yin, Hongbin Deng, Yi Luo, Ying Chen, Yunfei Yin, Rui Zhou, Ni Zhan and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jian QinDepartment of Urology Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Hanjing ZhouDepartment of Oncology, Laboratory of Immunity, Inflammation and Cancer, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xia LiDepartment of Oncology, Laboratory of Immunity, Inflammation and Cancer, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Hubin YinDepartment of Urology Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Hongbin DengDepartment of Oncology, Laboratory of Immunity, Inflammation and Cancer, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yi LuoDepartment of Oncology, Laboratory of Immunity, Inflammation and Cancer, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Ying ChenDepartment of Oncology, Laboratory of Immunity, Inflammation and Cancer, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yunfei YinDepartment of Oncology, Laboratory of Immunity, Inflammation and Cancer, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Rui ZhouDepartment of Oncology, Laboratory of Immunity, Inflammation and Cancer, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Ni ZhanDepartment of Oncology, Laboratory of Immunity, Inflammation and Cancer, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yu ZhengDepartment of Oncology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
Tao ZhangDepartment of Oncology, Laboratory of Immunity, Inflammation and Cancer, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Weiyang HeDepartment of Urology Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: This study evaluates the effectiveness and safety of combining radiotherapy with first-line chemotherapy and immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma (la/mUC). Methods: This retrospective study included patients with la/mUC who received first-line systemic treatment between January 2017 and December 2024. Two treatment strategies were compared: immunotherapy combined with chemotherapy followed by radiotherapy (ICRT group, n = 31) and immunotherapy combined with chemotherapy alone (ICT group, n = 73). Propensity score matching was used to reduce confounding and selection bias, yielding 30 matched patient pairs. Clinical endpoints included objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events. Results: After propensity score matching, the ICRT group showed significantly prolonged PFS (18.70 vs. 7.93 months; Conclusions: The addition of radiotherapy to first-line immunotherapy and chemotherapy demonstrated favorable clinical activity and an acceptable safety profile in patients with la/mUC.

Indexed as

ChemoradiotherapyImmune Checkpoint InhibitorsImmunotherapyUrinary Bladder NeoplasmsUrologic NeoplasmsAgedAged, 80 and overCombined Modality TherapyFemaleHumansMaleMiddle AgedNeoplasm MetastasisPropensity ScoreRetrospective StudiesTreatment OutcomeImmune Checkpoint InhibitorschemotherapyICISimmunotherapyradiotherapyUC

Identifiers

PMID42488678
PMCPMC13388569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.